Literature DB >> 8771163

Risk factors of respiratory failure in children with Guillain-Barré syndrome.

H Rantala1, M Uhari, J D Cherry, W D Shields.   

Abstract

Recently it was found that plasmapheresis and intravenous immunoglobulins are effective in treating patients with Guillain-Barré syndrome (GBS). However, these treatments are expensive and not without possible adverse effects. Because signs and symptoms predictive for respiratory failure in GBS would be helpful in targeting the treatment, risk factors for respiratory failure were evaluated in 120 children with GBS. Twenty children required assisted ventilation. None of the children without any of the following risk factors had respiratory failure. If the symptoms of GBS began within 8 days after a preceding infection, the odds ratio (OR) for respiratory failure was 4.9 [95% confidence intervals (CI): 1.3-18.5]. Cranial nerve involvement was more common in children who required assisted ventilation (15/20 versus 32/100, OR: 6.4, 95% CI: 2.1-19.1). A cerebrospinal protein level > 800 mg/L during the first week had an OR for assisted ventilation of 3.1 (95% CI of OR: 1.04-9.0). In the logistic multivariate model, all of these risk factors were associated with the need for assisted ventilation. On the basis of our findings, preventive treatment with either plasmapheresis or intravenous immunoglobulins could be directed to those children with any of the risk factors; for those patients without the risk factors, clinical monitoring would be satisfactory.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8771163     DOI: 10.1016/0887-8994(95)00189-1

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  9 in total

1.  EMG and duration of ventilatory support in children with Guillain-Barre syndrome.

Authors:  Fernando Ortiz-Corredor; Jorge Díaz-Ruiz; Alvaro Izquierdo-Bello
Journal:  Childs Nerv Syst       Date:  2006-03-25       Impact factor: 1.475

Review 2.  Respiratory dysfunction in Guillain-Barré Syndrome.

Authors:  David Orlikowski; Hélène Prigent; Tarek Sharshar; Frédéric Lofaso; Jean Claude Raphael
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

3.  Assessment of autonomic dysfunction in childhood guillain-barré syndrome.

Authors:  Mahmood Samadi; Babak Kazemi; Sona Golzari Oskoui; Mohammad Barzegar
Journal:  J Cardiovasc Thorac Res       Date:  2013-10-05

Review 4.  Respiratory aspects of neurological disease.

Authors:  M I Polkey; R A Lyall; J Moxham; P N Leigh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

5.  Approach to a child with acute flaccid paralysis.

Authors:  Sunit C Singhi; Naveen Sankhyan; Ravi Shah; Pratibha Singhi
Journal:  Indian J Pediatr       Date:  2012-07-12       Impact factor: 1.967

6.  Spectrum of Guillain-Barré syndrome in tertiary care hospital at Kolkata.

Authors:  Ujjal Kr Sarkar; Lalita Menon; Debabrata Sarbapalli; Ranabir Pal; Forhad Akhtar Zaman; Sumit Kar; Jyoti Singh; Mohan Mondal; Soma Mukherjee
Journal:  J Nat Sci Biol Med       Date:  2011-07

7.  Clinical predictors and electrodiagnostic characteristics in patients with Guillain-Barré syndrome with respiratory failure: a retrospective, matched case-control study.

Authors:  Kanchana Charoentanyarak; Apiradee Singjam; Jittima Saengsuwan
Journal:  PeerJ       Date:  2022-02-10       Impact factor: 2.984

8.  Distinct Clinical Characteristics of Pediatric Guillain-Barré Syndrome: A Comparative Study between Children and Adults in Northeast China.

Authors:  Xiujuan Wu; Donghui Shen; Ting Li; Bing Zhang; Chunrong Li; Mei Mao; Jixue Zhao; Kangding Liu; Hong-Liang Zhang
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

9.  A Predictive Model for Respiratory Failure and Determining the Risk Factors of Prolonged Mechanical Ventilation in Children with Guillain-Barre Syndrome.

Authors:  Mohammad Barzegar; Vahideh Toopchizadeh; Diena Golalizadeh; Ali Pirani; Fatemeh Jahanjoo
Journal:  Iran J Child Neurol       Date:  2020
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.